Navigation Links
FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder
Date:8/2/2010

ar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='99751994';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.octapharma.com/corporate/02_the_company/02_people/01_management_board/01_management_board.php">Flemming Nielsen, President of Octapharma USA, the rapidly growing U.S. division of Octapharma AG, one of the world's largest human protein products manufacturers. "wilate® has received seven years of marketing exclusivity as a result of the evidence suggesting wilate® is as efficacious and safer than Humate P."

The FDA has approved wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

wilate® is the first double virus inactivated VWF/FVIII (von Willebrand Factor / Factor FVIII), high-purity concentrate, utilizing the solvent/detergent (S/D) process and a special terminal dry-heating (TDH) step. The selected purification processes isolates the VWF/FVIII complex under highly protein-protecting conditions, resulting in a 1:1 ratio of VWF:RCo (ristocetin cofactor) to FVIII activity that is similar to
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
8. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
9. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
10. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
11. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  ResMed (NYSE: RMD ) ... agreement to acquire Curative Medical, a privately-held ... breathing medical devices and accessories. ... leadership in sleep and respiratory medicine, will ... suffering from sleep-disordered breathing and ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... 2011 BD (Becton, Dickinson and Company) ... technology company, announced today that it is donating $325,000 ... earthquake and tsunami in Japan. BD will distribute these ... AmeriCares, American Red Cross, Direct Relief International, Heart to ...
... March 15, 2011 New Image Global, Inc., ... recently joined forces with the disability advocacy group, ... donated artificial limbs to candidates disabled by amputation ... manufacturing facility in Santiago, Dominican Republic.) Under the ...
Cached Medicine Technology:BD Donates $325,000 for Japan Earthquake and Tsunami Relief Efforts 2
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic ... across Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach ... 30. , “Peach State Health Plan and our parent company, Centene Corporation, are ...
(Date:7/31/2015)... ... , ... Like nearly every other form of surgery, it shouldn't come as ... and less intrusive and painful. Leading these advances in the United States has ... stands as the only doctor in the United States who is qualified to practice, ...
(Date:7/31/2015)... ... 31, 2015 , ... Florida Hospital Tampa has started treating ... for targeted delivery of fluids to selected sites in the peripheral vascular system. ... with the device that provides direct, local delivery of chemotherapy to the pancreas. ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on July ... heroin use and eventual overdoses. Thricefold deaths have held steady over the last “couple ... the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. Many ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... and other chemicals boost their odds of respiratory ... News) -- Frequent exposure to hospital cleaning products ... according to a U.S. study that included 3,650 ... The researchers found that nurses regularly exposed to ...
... 20 MPR ( Monthly Prescribing Reference ) is pleased to ... For over 25 years, physicians and other healthcare professionals ... our drug database for up-to-date, concise drug information at the point-of-care.The ... will also offer a number of added features and functionality: , ...
... Jan. 20 Northern Trust announced today,that it ... North Shore-LIJ Health,System, the nation,s third largest not-for-profit ... custodian, benefit payment, plan accounting,and investment risk and ... invested funds. , "North ...
... IT pioneer doubles annual revenues, brings on hundreds of ... today announced 200 percent revenue growth in 2008. ... system, integrated delivery network (IDN) and health information exchange ... bookings and the addition of some 200 hospitals to ...
... to target only the tumor, researchers explain , , ... therapy that uses beads soaked with anti-cancer agents has ... studies. , Transarterial chemoembolization (TACE) attacks liver ... cancer-killing chemotherapeutic agents are delivered to the blood vessel ...
... /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) (,Renhuang, ... People,s Republic of China (,PRC,),today announced that it ... new,independent auditor, effective January 9, 2009. Moore ... was dismissed on the same,day. , ...
Cached Medicine News:Health News:Cleaning Products Up Nurses' Asthma Risk 2Health News:MPR Re-Launches its Up-to-Date Drug Reference Website 2Health News:Northern Trust Named Global Custodian to North Shore-LIJ Health System in New York 2Health News:Carefx Reports 200% Year-Over-Year Revenue Growth in 2008 as Demand Grows for Solutions Focused on Clinical Decision Making 2Health News:Carefx Reports 200% Year-Over-Year Revenue Growth in 2008 as Demand Grows for Solutions Focused on Clinical Decision Making 3Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 2Health News:Tiny Chemo Beads Boost Liver Cancer Outcomes 3Health News:Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor 2
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: